What it's for (Indications)
- This medicinal combination of guaifenesin and terbutaline is primarily indicated for the symptomatic relief of productive cough and bronchospasm associated with various respiratory conditions.
- It is used in patients suffering from diseases such as bronchial asthma, chronic bronchitis, emphysema, and other chronic obstructive pulmonary disorders where both mucus accumulation and airway constriction are prominent.
- Guaifenesin acts as an expectorant, facilitating the loosening and removal of tenacious tracheobronchial secretions, thereby making coughs more productive.
- Terbutaline, a selective beta-2 adrenergic agonist, works to relax bronchial smooth muscles, leading to bronchodilation and improved airflow.
- This dual action aims to alleviate respiratory distress by clearing airways and reducing airway resistance, enhancing overall respiratory function and patient comfort during episodes of respiratory exacerbation.
- The therapeutic goal is to improve breathing and facilitate the expulsion of mucus, which contributes to the overall management of acute and chronic respiratory tract conditions characterized by these symptoms.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of guaifenesin and terbutaline combination therapy must be individualized based on the patient's age, weight, medical condition, and response to treatment. While specific formulations and strengths vary, typical adult dosages might involve oral administration of a fixed-dose combination, often as a syrup or tablet, usually taken two to three times daily. For instance, a common regimen could be a specific strength of terbutaline sulfate combined with guaifenesin, adjusted as per physician's discretion. Pediatric dosages are significantly lower and are typically calculated based on body weight or surface area, strictly adhering to age-appropriate guidelines and avoiding exceeding recommended maximums. It is crucial to administer this medication exactly as prescribed by a healthcare professional and not to exceed the recommended dose or frequency, as doing so can increase the risk of adverse effects. Patients should be advised on the correct measuring devices for liquid formulations to ensure accurate dosing. Adjustments may be necessary in patients with renal or hepatic impairment, requiring careful clinical assessment. |
Safety & Warnings
Common Side Effects
- As with any pharmacotherapeutic agent, the guaifenesin and terbutaline combination can elicit a range of side effects, primarily attributed to the beta-2 adrenergic agonist component, terbutaline.
- Common adverse reactions include tremors, nervousness, restlessness, headache, dizziness, and palpitations.
- Some patients may experience tachycardia (increased heart rate), mild hypertension, or muscle cramps, particularly at higher doses.
- Gastrointestinal disturbances such as nausea, vomiting, or stomach discomfort are also possible, particularly with guaifenesin, though generally mild and transient.
- Less common but more serious side effects may include cardiac arrhythmias, chest pain, and paradoxical bronchospasm, where the airway constriction paradoxically worsens immediately after administration; this requires immediate medical intervention.
- Patients should be advised to report any persistent or severe side effects to their healthcare provider promptly.
- Hypersensitivity reactions, though rare, can also occur, presenting as rash, itching, or swelling, and necessitate discontinuation of the drug.
Serious Warnings
- Black Box Warning: **Serious Warnings Regarding Cardiovascular and Paradoxical Bronchospasm Risks** While oral terbutaline historically carried a Black Box Warning primarily for its use as a tocolytic (prevention of preterm labor) due to serious maternal cardiac events and death, this specific combination product (guaifenesin + terbutaline) for respiratory indications does not typically carry an identical FDA Black Box Warning for its bronchodilator use. However, it is imperative to issue a **Serious Warnings** section emphasizing the significant risks associated with the terbutaline component when used for respiratory conditions. Beta-adrenergic agonists, including terbutaline, can produce clinically significant cardiovascular effects in some patients, including increases in pulse rate, blood pressure, and/or symptoms of cardiac arrhythmia and palpitations. There have been rare reports of ischemic events, and this drug should be used with extreme caution in patients with pre-existing cardiovascular disorders, including coronary insufficiency, arrhythmia, and hypertension. Fatalities have been reported in association with excessive use of sympathomimetic drugs in patients with asthma. Additionally, paradoxical bronchospasm, which can be life-threatening, may occur with the use of beta-agonist bronchodilators; if it occurs, the product should be discontinued immediately, and alternative therapy instituted. Patients should be instructed to seek immediate medical attention if their condition worsens, if the medication becomes less effective, or if they experience symptoms such as chest pain, dizziness, or severe palpitations. These serious risks underscore the importance of strict adherence to prescribed dosages, avoidance of overuse, and continuous medical supervision during therapy.
- This medication requires careful use and patient monitoring due to several important warnings, predominantly related to the terbutaline component.
- Terbutaline, being a beta-2 agonist, can cause significant cardiovascular effects, including increases in heart rate, blood pressure, and potential for arrhythmias, necessitating extreme caution in patients with pre-existing cardiovascular disorders, hypertension, or ischemic heart disease.
- It can also cause central nervous system stimulation, manifesting as nervousness, tremors, and insomnia.
- Paradoxical bronchospasm, a life-threatening reaction, can occur with beta-agonist use; if this happens, the medication should be discontinued immediately, and alternative therapy instituted.
- Use with caution in patients with diabetes mellitus, as beta-agonists can increase blood glucose levels, and in patients with hyperthyroidism due to potential exacerbation of thyroid symptoms.
- Patients with convulsive disorders should also be monitored closely.
- Prolonged use or overuse of beta-agonists can lead to tachyphylaxis or reduced effectiveness, and patients should be advised not to exceed prescribed doses.
- Concurrent use with other sympathomimetics can intensify adverse effects.
- The guaifenesin component requires caution in patients with chronic cough associated with smoking, asthma, or emphysema, where persistent cough may indicate a serious condition requiring further evaluation.
How it Works (Mechanism of Action)
The therapeutic efficacy of the guaifenesin and terbutaline combination stems from the complementary actions of its two active components. Guaifenesin functions as an expectorant by increasing the volume and decreasing the viscosity of secretions in the respiratory tract. It achieves this by stimulating secretory glands, which results in an increased output of thinner, less viscous mucus. This change in consistency facilitates the clearance of mucus through ciliary action and coughing, making coughs more productive and reducing chest congestion. Terbutaline sulfate is a direct-acting sympathomimetic amine with predominant beta-2 adrenergic agonist activity. Its primary action is the relaxation of bronchial smooth muscle, leading to bronchodilation. This occurs via activation of adenyl cyclase, which increases intracellular cyclic AMP (cAMP) levels, ultimately promoting relaxation of smooth muscle cells in the airways. This bronchodilation improves airflow and alleviates bronchospasm, thereby enhancing respiratory function. The synergistic effect of these two agents addresses both the mucolytic and bronchodilatory needs in respiratory conditions.
Commercial Brands (Alternatives)
No other brands found for this formula.